1. Quintin T. Chipley, M.A., M.D.

2.  This presenter has no funding from any institution, corporation, or agency regarding the content of this presentation.  Although he loves his work at the University of Louisville as the Counseling Coordinator for the Health Sciences Center students, that institution should in no way be held responsible for the content of this presentation.

3.  Even Acute Conditions often require months, and post-acute condidtions may need years to remit after substance cessation Clinical Case example: Parkinsonian syndrome secondary to Nicorette gum abuse (proposed mechanism: The over-triggered ACH neurons cause the dopamine producing neurons to constantly exhaust their supply, finally leading to dopamine depletion.)

4.  Co-Morbid conditions are sometimes the abuse of a substance (perhaps leading to addiction) in an effort to self-medicate Clinical Case example: Tobacco use in Chronic Schizophrenia (Proposed mechanism: the micro-jolts of dopamine released after nicotine acts on ACH neurons gives the patient a “micro respite” from confused thoughts)

5.  Increase Psychotic Disorders, even among people without a genetic predisposition: One study indicates an extra 1 in 1400 people will develop chronic psychosis. The intereaction effect with a genetic predisposition becomes much larger  Depressive and anxiety disorders are probably even more prevalent and with greater social and financial burden

6.  Dose dependent  Age dependent: the younger the abuser, the greater the risk

7. D9-THC Cannabidiol here

8.  THC is the active agent in the “mind expanding” hallucinatory-type experiences. These include distortions in perception of time an space. (A metabolite produce in the liver may also be responsible for increased heart rate, anxiety. a.k.a sympathomemetic.)  Cannabidiol produces sedation and even reduces distortions

9.  D9-THC dose-response curve keeps on rising: The greater the dose, the greater the response  Cannabidiol has a dose-response curve that tends to “flatten” out: after a certain plasma level is reach, an increase in plasma level does not create more effect

10.  In Cannabis sativa the ratio of D9-THC: Cannabidiol is high even before horticultural selection  In Cannabis indica the ratio of D9–THC : Cannabidiol is not nearly as high

11.  By the time we consider individual differences in human physiology (liver function: acytelation and cytochrome p450 actions), differences in genetic predispositions for psychotic, mood, and anxiety disorders, and differences in relative concentrations of the major psychoactive components of Cannabis as acquired on the streets and in “pharmacies” we are looking at a crap-shoot regarding the outcome.

12.  If you remember, it did not take long for major tobacco companies to learn how to use post-harvest chemistry (essentially free- basing tobacco) to make the nicotine more bioavailable, rendering the product more popular.  How long do you think it will be before research shows a way to close the ring in Cannabidiol so that it becomes D9-THC?

13. D9-THC Cannabidiol here

14.  Obviously, substance use abstinence is first  Should an anti-psychotic medication be used in the presentation of psychosis secondary to Cannabis use?  Frankly, there is not enough evidence –based material in the literature to say.  If you follow the theory-based notion that the longer a person stays in a psychotic state, the more permanent is the neuronal architecture change, then aggressive treatment is warranted. But anti-psychotic meds have considerable risks.

15.  Greater than for other substituted amphetamines (MDMA, for example) and non-substituted amphetamines (substituted refers to the addiction of side groups, such as methyl groups, onto the basic molecule)  Cognitive deficits (memory, concentration), social intelligence deficits (loss of attention to subtle social signals), motor deficits

16.  Causes irreparable harm to the mid section of the neuronal axon that prevents recovered adumbration of the dendrites and butons (Think of pruning back a bush or tree so severely that the plant loses ability to create new sprouts; or trimming the root-ball so severely that new absorptive ends cannot grow.)

17.  Mechanisms of why the chemical cause the cellular pathophysiology are not clearly understood. Perhaps related to chronic intracranial hyperthermia (YES! The amphetamine dysregulates metabolic control so that proteins “cook!”), but other stimulants have similar temperature increases without the same chronic damage

18.  Definitely compromises the tight-junctions of the endothelial cells of the cerebral vasculature, which weakens the blood-brain barrier and allows leukocytes to cross; if HIV infection is present, these leukocytes take the virus into the neuronal matrix and accelerates HIV-related dementia

19.  Substance use abstinence  No distinct pharmacological remedy is suggested in the literature  Talk-Therapy and group therapy to amplify as much as is possible social-feedback

20.  Nutrition related  Non-nutrition related

21.  Thiamine deficiency (lack in diet or poor absorption due to gut-lining inflammation) causes certain neurons that rapidly metabolize glucose to be unable to balance osmotic pressures across the membrane except by swelling, thus killing the neuron.  Basically: low thiame + carbohydrate = cell death

22.  Wernicke’s is the acute phase, with ataxia, slurring of speech, and confusion; all of which sounds like acute intoxication and therefore is easily missed when you are looking at a chronic alcoholic  Korsakoffs is the persistent condition. Characterized by confabulation: the act of unconsciously manufacturing narratives to “replace” lost content so that an inner-sense of congruence is maintained even if it does not relate to external reality.

23.  Prevention: the “VA cocktail” that is rich in thiamine  Intervention: if a patient has missed the chance for preventative dosing with thiamine, and if the first signs of Wernicke’s encephalopathy are noted, an intra-muscular dose of thiamine might help  Patience for the patient: Once Korsakoff’s is present, there really is no known cure. When they confabulate, they are not “lying.”

24.  Alcohol Related Dementia seems to be the new term of choice; some say it is the leading cause of dementia; some say second leading cause  Studies that scan brains show diminished blood flow to both the cortical tissue (i.e.- top, thin layer of the brain) and subcortical structures when compared to age-matched healthy normals

25.  The mechanism seems to be different than for non-alcohol related Vascular Dementia  Pathophysiology is poorly understood. A strong hypothesis is that chronic oxidative damage to the cells that line the blood vessels is the cause.

26.  When you graph dose vs benefit, a “J” curve emerges: This means that “no consumption” people have greater risk of dementia than “low consumption” people,” but “high consumption people” have dementia risks greater than either of the others. Since the notion of “low consumption” is absurd for the person with the disease of alcoholism, it is pretty easy to see where they end up on the curve.  TAKE HOME MESSAGE: “Earth people” (normals) may get a benefit; alcoholics cannot.

27.  I only found one case-report from Europe using memantine  I found no reports regarding use of classic anti-dementia drugs (Arricept, etc)

28.  Aho L, Karkola K, Iuusela I, Alafuzoff I. Heavy alcohol consumption and neuropathological lesions: a post-mortem human study. J Neurosci Res2009 Sep;87(12):2786-92. PMID: 19382227  Bhattacharyya S, Fusar-Poli P, Borgwardt S, Martin-Santos R, Nosarti C, O'Carroll C, Allen P, Seal ML, Fletcher PC, Crippa JA, Giampietro V, Mechelli A, Atakan Z, McGuire P. Modulation of mediotemporal and ventrostriatal function in humans by Delta9-tetrahydrocannabinol: a neural basis for the effects of Cannabis sativa on learning and psychosis. Arch Gen Psychiatry. 2009 Apr;66(4):442-51. PMID: 19349314  Bhattacharyya S, Morrison PD, Fusar-Poli P, Martin-Santos R, Borgwardt S, Winton-Brown T, Nosarti C, O' Carroll CM, Seal M, Allen P, Mehta MA, Stone JM, Tunstall N, Giampietro V, Kapur S, Murray RM, Zuardi AW, Crippa JA, Atakan Z, McGuire PK. Opposite effects of delta-9-tetrahydrocannabinol and cannabidiol on human brain function and psychopathology. Neuropsychopharmacology. 2010 Feb;35(3):764-74. PMID: 19924114  Bossong MG, Niesink RJ. Adolescent brain maturation, the endogenous cannabinoid system and the neurobiology of cannabis-induced schizophrenia. Prog Neurobiol. 2010 Jul 15. PMID: 20624444  Di Forti M, Morgan C, Dazzan P, Pariante C, Mondelli V, Marques TR, Handley R, Luzi S, Russo M, Paparelli A, Butt A, Stilo SA, Wiffen B, Powell J, Murray RM. High-potency cannabis and the risk of psychosis. Br J Psychiatry. 2009 Dec;195(6):488-91. PMID: 19949195

29.  Gold MS, Kobeissy FH, Wang KK, Merlo LJ, Bruijnzeel AW, Krasnova IN, Cadet JL. Methamphetamine- and trauma-induced brain injuries: comparative cellular and molecular neurobiological substrates. Biol Psychiatry. 2009 Jul 15;66(2):118-27. PMID: 19345341  Gupta s, Warner J. Alcohol-related dementia: a 21st-century silent epidemic? Br J Psychiatry. 2008 Nov; 193(5):351-3. PMID: 18978310  Hedges DW, Woon FL, Hoopes SP. Caffeine-induced psychosis. CNS Spectr. 2009 Mar;14(3):127-9. PMID: 19407709  Hickman M, Vickerman P, Macleod J, Lewis G, Zammit S, Kirkbride J, Jones P. If cannabis caused schizophrenia--how many cannabis users may need to be prevented in order to prevent one case of schizophrenia? England and Wales calculations. Addiction. 2009 Nov;104(11):1856-61. PMID: 19832786  Jordaan GP, Nel DG, Hewlett RH, Emsley R. Alcohol-induced psychotic disorder: a comparative study on the clinical characteristics of patients with alcohol dependence and schizophrenia. J Stud Alcohol Drugs. 2009 Nov;70(6):870-6. PMID: 19895763  Krasnova IN, Cadet JL. Methamphetamine toxicity and messengers of death. Brain Res Rev. 2009 May;60(2):379-407. PMID: 19328213  Lin SK, Huang MC, Lin HC, Pan CH. Deterioration of intelligence in methamphetamine-induced psychosis: comparison with alcohol dependence on WAIS-III. Psychiatry Clin Neurosci. 2010 Feb;64(1):4-9. PMID: 19968830

30.  Mahajan SD, Aalinkeel R, Sykes DE, Reynolds JL, Bindukumar B, Adal A, Qi M, TohJ, Xu G, Prasad PN, Schwartz SA. Methamphetamine alters blood brain barrier permeability via the modulation of tight junction expression: Implication for HIV-1 neuropathogenesis in the context of drug abuse. Brain Res. 2008 Apr 8;1203:133-48. PMID: 18329007  Malone DT, Jongejan D, Taylor DA. Cannabidiol reverses the reduction in social interaction produced by low dose Delta(9)-tetrahydrocannabinol in rats. PMID: 19393686  Morgan CJ, Freeman TP, Schafer GL, Curran HV. Cannabidiol attenuates the appetitive effects of Delta 9-tetrahydrocannabinol in humans smoking their chosen cannabis. Neuropsychopharmacology. 2010 Aug;35(9):1879-85. PMID: 20428110  Müller H, Sperling W, Köhrmann M, Huttner HB, Kornhuber J, Maler JM. The synthetic cannabinoid Spice as a trigger for an acute exacerbation of cannabis induced recurrent psychotic episodes. Schizophr Res. 2010 May;118(1-3):309-10. PMID: 20056392  Pierre JM. Psychosis associated with medical marijuana: risk vs. benefits of medicinal cannabis use. Am J Psychiatry. 2010 May;167(5):598-9. PMID: 20439399  Tian C, Murrin LC, Zheng JC. Mitochondrial fragmentation is involved in methamphetamine-induced cell death in rat hippocampal neural progenitor cells. PLoS One. 2009;4(5):e5546. Epub 2009 May 14. PMID: 19436752  Yuan J, Darvas M, Sotak B, Hatzidimitriou G, McCann UD, Palmiter RD, Ricaurte GA. Dopamine is not essential for the development of methamphetamine-induced neurotoxicity. J Neurochem. 2010 Jun 1. PMID: 20533999